Iomai Launches Phase 1/2 Safety Study of Dose-Sparing Patch for Use With Pandemic Influen...( - Trial to Assess Safety and Dose-...),Health

- Trial to Assess Safety and Dose-Sparing Capability of Iomai Adjuvant

Patch -

GAITHERSBURG, Md., Sept. 6 /PRNewswire-FirstCall/ -- Iomai Corporation (Nasdaq: IOMI) today announced that it has begun dosing in a Phase 1/2 study that will assess the safety and dose-sparing capability of the company's immunostimulant patch when used in combination with an injected H5N1 influenza vaccine.

The Iomai patch, which contains a powerful immune-stimulating adjuvant, is used in conjunction with an injected influenza vaccine and may generate an immune response with small amounts of vaccine antigen. If successful, Iomai's approach may expand the pandemic influenza vaccine supply in the event of an influenza pandemic. This clinical trial is funded through an advanced development contract from the U.S. Department of Health and Human Services.

"This is the first human trial of the Iomai immunostimulant patch for use with a pandemic-like influenza vaccine, and the results of this study will give us crucial information about the ability of the patch to extend the vaccine supply in the event of a pandemic," said Stanley C. Erck, president and chief executive officer of Iomai. "Our patch is designed to solve the pressing problem of inadequate pandemic vaccine stocks, and we believe the results of this trial will validate our unique and flexible dose-sparing approach."

The study will enroll as many as 500 subjects, who will receive either a placebo injection or one of three dosages of pandemic influenza vaccine. Patients will receive a booster shot of placebo or vaccine 21 days later. Of these patients, approximately one-third will receive no immunostimulant patch, one-third will
'/>"/>